Galectin Therapeutics Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 8.193 million compared to USD 6.102 million a year ago. Net loss was USD 8.449 million compared to USD 6.114 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.11 a year ago. For the half year, operating loss was USD 14.510 million compared to USD 9.686 million a year ago. Net loss was USD 14.787 million compared to USD 9.670 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.17 a year ago. Operating loss was USD 8.193 million compared to USD 6.102 million a year ago.